PROCEPT BioRobotics Corp (PRCT) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US74276L1052

Price
20.30 USD
Market cap
1.16 bn USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

PROCEPT BioRobotics Corp financials

Fiscal year2025
Revenue308.05 m USD
Gross profit196.23 m USD
Operating income-103.86 m USD
EBIT-104.02 m USD
Net income-95.57 m USD
Diluted EPS – continuing operations-1.72 USD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.